Trial Profile
Assessment of Histopathological Response to Combination Chemotherapy With Oxaliplatin, Irinotecan, Fluorouracil and Bevacizumab in Patients With Peritoneal Metastasis From Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Carcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms CARCINOSIS
- 19 Jan 2020 Status changed from recruiting to discontinued.
- 18 May 2017 Planned number of patients changed from 30 to 50.
- 02 Apr 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.